Related Experiment Video
Updated: Jun 5, 2025

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
Targeting Tn Antigen Suppresses Aberrant O-Glycosylation-Elicited Metastasis in Breast Cancer
Tan Du1, Xichen Dong1, Jingyu Tan1
1Medical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
Abstract:
The Tn antigen, a truncated O-glycan representing aberrant mucin-type O-glycosylation, is frequently observed in human breast cancer. However, the functional role of Tn antigen in breast cancer metastasis remains insufficiently investigated. This study aimed to elucidate the expression profile of Tn antigen in breast cancer and its potential as a therapeutic target for inhibiting metastasis. Immunohistochemical staining was performed to determine the levels of Tn antigen expression in breast cancer tissues and its clinical relevance was analyzed accordingly. Tn-positive breast cancer cell lines were generated through disruption of the Cosmc gene. The functional roles of Tn antigen in breast cancer metastasis were studied in both in vitro and in vivo models. Western blotting and immunofluorescence staining were employed to investigate the molecular mechanisms by which Tn antigen promotes breast cancer metastasis. Our findings revealed that Tn antigen was prevalent in breast carcinomas, particularly within metastatic lesions. Tn antigen expression was positively correlated with lymph node metastasis and poorer patient survival. Tn antigen-expressing breast cancer cells exhibited enhanced invasiveness and metastasis, along with significant activation of EMT and FAK signaling pathways. Targeting Tn-positive cells with HPA (Helix pomatia agglutinin) demonstrated the suppression of invasive and metastatic capabilities, EMT program, and FAK signaling in vitro, as well as reduced pulmonary metastasis in a xenotransplant mouse model. This study reveals that Tn antigen-mediated aberrant O-glycosylation plays a contributing role in breast cancer metastasis, which may serve as a potential therapeutic target in clinical practice.
Insights
Aberrant O-glycosylation, marked by the Tn antigen, fuels breast cancer metastasis. Targeting Tn-positive cells with Helix pomatia agglutinin (HPA) inhibits cancer spread and improves survival, suggesting a new therapeutic strategy.
Area of Science:
- Oncology
- Glycobiology
- Cancer Metastasis
Background:
- Aberrant mucin-type O-glycosylation, characterized by the Tn antigen, is prevalent in human breast cancer.
- The specific role of Tn antigen in breast cancer metastasis requires further investigation.
Purpose of the Study:
- To investigate the expression profile of Tn antigen in breast cancer.
- To evaluate the therapeutic potential of targeting Tn antigen for inhibiting metastasis.
Main Methods:
- Immunohistochemical staining to assess Tn antigen expression and clinical relevance.
- Generation of Tn-positive breast cancer cell lines by Cosmc gene disruption.
- In vitro and in vivo models to study metastasis, utilizing Western blotting and immunofluorescence.
Main Results:
- Tn antigen is prevalent in breast carcinomas, especially metastatic lesions, and correlates with lymph node metastasis and poorer survival.
- Tn antigen-positive cells show enhanced invasiveness, metastasis, epithelial-mesenchymal transition (EMT), and FAK signaling.
- HPA treatment suppressed metastasis, EMT, and FAK signaling in vitro and reduced pulmonary metastasis in vivo.
Conclusions:
- Tn antigen-mediated aberrant O-glycosylation contributes to breast cancer metastasis.
- Tn antigen represents a potential therapeutic target for inhibiting breast cancer progression and metastasis.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

